BTK Inhibitors: An Emerging Target in Multiple Sclerosis


This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an educational grant from Sanofi.


Multiple sclerosis (MS) is a chronic inflammatory condition that affects approximately 1 million US adults. The disease is marked by central nervous system (CNS) demyelination that results in fatigue, spasticity, and pain, among many other symptoms that negatively impact quality of life. Appreciation for the need to prevent increasing CNS damage and disability accumulation in patients with MS continues to drive efforts to identify new disease-modifying therapies with the potential for greater efficacy and long-term safety. Among the new candidates are multiple Bruton’s tyrosine kinase (BTK) inhibitors, which exert their therapeutic effects via targeting of B-cell receptor signaling.

Join our esteemed clinician faculty for a review of the clinical rationale for BTK inhibition in MS treatment, and the efficacy and safety of BTK inhibitor therapies currently in late-stage development. The program will conclude with an interactive mechanism of action activity and access to a downloadable resource.


Daniel S. Reich, MD, PhD
Dr. Reich is Chief, Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), USA. He appears here in his private capacity, as an approved Outside Activity, and the views and opinions here do not represent those of NINDS or NIH.

Release date: December 15, 2022
Expiration date: December 15, 2023
Estimated time to complete activity: 45 minutes

This educational activity has been designed to meet the needs of neurologists, primary care physicians, nurse practitioners, physician assistants, and other advanced health care professionals who manage patients with MS.


Upon completion of this educational activity, participants should be able to:

  • Improve knowledge of clinicians on the role of BTK inhibition in MS management
  • Describe the mechanisms of action for emerging BTK inhibitors
  • Recall available safety and efficacy data for emerging BTK inhibitors

There are no fees for participating and receiving CME credit for this activity. During the period of December 15, 2022 through December 15, 2023 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Daniel S. Reich, MD, PhD
Collaborative Research: Abata Therapeutics, Sanofi

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest